Matthew Vincent Dolan, SVP Corporate Strategy-Develop at DEXCOM INC (DXCM), sold 18,662 shares at $106.27 ($2.0M) on 2023-03-13, disclosed to the SEC on 2023-03-14.
Open-market sale of $2.0M DXCM by SVP Corporate Strategy-Develop. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $111.40 | 787 | $88K | 4.4% |
| 2 | $111.40 | 1,370 | $153K | 7.6% |
| 3 | $111.40 | 1,650 | $184K | 9.1% |
| 4 | $111.40 | 2,397 | $267K | 13.3% |
| 5 | $106.27 | 6,229 | $662K | 32.9% |
| 6 | $106.27 | 6,229 |
| $662K |
| 32.9% |
| Total | $107.98 avg | 18,662 | $2.0M | 100% |
| Filing → |
| DXCM | SELL | 2024-04-16 | $548K | — | Filing → |
| DXCM | SELL | 2024-03-19 | $1.1M | — | Filing → |
| DXCM | SELL | 2024-03-14 | $1.8M | — | Filing → |